We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current SNPHY market cap is 3.61B. The company's latest EPS is JPY 73.3606 and P/E is 0.13.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 241.95B | 265.61B | 266.81B | 282.56B | 303.51B |
| Operating Income | 33.55B | 12.66B | 33.87B | -4.9B | 30.97B |
| Net Income | 21.71B | 6.65B | 27.19B | -14.98B | 26.7B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 408.77B | 402.35B | 459.98B | 421.18B | 435.7B |
| Total Liabilities | 106.21B | 95.3B | 123.13B | 127.88B | 130.33B |
| Total Equity | 302.56B | 307.05B | 336.84B | 293.3B | 305.37B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 39.95B | 38.81B | 46.04B | 37.15B | 72.65B |
| Investing | -5.17B | -53.36B | -35.17B | -26.78B | -6.15B |
| Financing | -12.73B | -16.69B | 5.56B | -37.22B | -34.03B |
| Market Cap | 3.61B |
| Price to Earnings Ratio | 0.13 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.04 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 364M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.62 (5.85%) |
| Company Name | Santen Pharmaceutical Company (PK) |
| Address |
4-20 ofuka town higashiosaka, osaka 533-8651 |
| Website | https://www.santen.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
